Ukugada nge-Sero kwe-IgG kuya kwi-SARS-CoV-2 emitholampilo yabakhulelwe ezibhedlela ezimbili eKhenya.

Ukutheleleka nge-SARS-CoV-2 okugcina kungatholakalanga kwethula inkinga ekulandeleleni inqubekela phambili yale mpathamhlaba nokubekwa kwezindlela zokuyilawula eKhenya.

Sibheke ukwanda kwe-IgG kwi-SARS-CoV-2 emasampuleni egazi lomama abathola usizo lwangaphambi kokubeletha ezibhedleleni ezi-2 eKhenya.

Sisebenzise i-IgG ELISA ukubheka ukukhuphuka kwamaphrotheni e-SARS-CoV-2 bahlela imiphumela yokuhlola ukuzwela nokucacisa.

Esibhedlela i-Kenyatta National Hospital, eNayrobhi i-seroprevalence ngoNcwaba(Agasti) ka-2020 ibiwu-49.9% (95% CI 42.7-58.0).

Esibhedlela i-Kilifi County Hospital i-seroprevalence inyuke yasuka ku-1.3% (95% CI 0.04-4.7) ngoMandulo yaya ku-11.0% (95% CI 6.2-16.7) ngoLwezi ka-2020.

Kube nokudluliseka kwe-SARS-CoV-2 okukhulu okunganakwanga ezingxenyeni zeNayrobhi nasezifundeni zaseKilifi.

Abantu baseKhenya abaningi kungenzeka ukuthi bathola i-COVID-19 bengazi ngo-2021.

Abacwaningi babika ukuthi ngo-2021, amasampula atholakala ebantwini besifazane abazithwele eKhenya batholakale benamasosha omzimba egciwane elidala i-COVID-19.

Lokhu kusho ukuthi bebeke batheleleka ngaphambilini, noma babenegciwane ngaleso sikhathi, kodwa iningi lalokhu kutheleleka alivelange emiphumeleni yokuhlolwa nge-PCR.

Abacwaningi bathi ukwanda kwe-COVID-19 kungenzeka ukuthi bekubukelwa phansi eKhenya ngalesiya sikhathi.

Ngokujwayelekile, ohulumeni badinga ulwazi olungaphumi eceleni lokuthi bangaki abantu abanalesi sifo ukuze kubekwe izindlela zokusilawula nezokuselapha.

EKhenya, abantu abaningi abayanga ukohlolela i-COVID-19 nokho.

Lokhu kungadalwa ukuthi izakhamuzi zisencane ngeminyaka, futhi abaningi bebenganazo izinkomba noma bebenezinkomba ezingezimbi.

Ososayensi bathi ukukala ukwanda kwamasosha omzimba e-SARS-CoV-2 enye yezindlela yokugagula izibalo zabathelelekile.

Amasosha omzimba angamaphrotheni athize akheka emzimbeni ngenxa yesifo esithize, ubukhona bawo kusho ukuthi usuke watheleleka.

Kulolu cwaningo, abacwaningi babheke ukwanda kwamashosha e-SARS-CoV-2 kwabesimame abazithwele ezibhedlela ezi-2 eNayrobhi naseKilifi, eKhenya.

Bahlolele amasosha e-SARS-CoV-2 emasampuleni egazi kulaba besifazane.

Baqhathanise izibalo zamasampula atholakale enaso isifo nezibalo eziqinisekiswe ukuhlola nge-PCR ukuthi kunesifo se-SARS-CoV-2 abazithole emnyangweni wezempilo kulezi zindawo.

Abacwaningi baphinde babheka amarekhodi ezempilo babhala ukuthi amasampula athathwa nini, neminyaka yabo, izindawo zokuhlala, izinyanga zokukhulelwa, nobukhona nokungabikho kwezimpawu ze-COVID-19.

Bathole ukuthi uhhafu wamasampula aseNayrobhi atholakale enamasosha e-SARS-CoV-2, futhi phakathi kuka 1.3% no-10% eKilifi.

I-PCR ivumelene nokuthi ukutheleleka bekungaphansi kuka 1% ezindaweni zombili, okusho ukuthi izibalo zokutheleleka azibikwanga ngokwanele.

Bathole nokuthi abesifazane abawu-7% kuphela babike izimpawo eziqondene ne-COVID-19, okusho ukuthi ukutheleleka okuningi bekungenazimpawu.

Abacwaningi bathi kungabangcono ukuhlolela amasosha e-SARS-CoV-2 ukuze kubonakale izibalo zangempela zabantu abathelelekile eKhenya.

Bayaqinisekisa nokho ukuthi basebenzise imininingwane yeziguli ibiyimfihlo, okusho ukuthi bebengeke bekwazi ukuqhathanisa neminye imininingwane ukuqinisekisa imiphumela yabo.

Abacwaningi baphinde basho ukuthi bebeshoda ngolwazi lokwehla kwamasosha, okubalulekile ekugaguleni kahle ezibalo zabathelelekile.

Lolu cwaningo beluyingxenye lohlelo olukhulu lokuqapha i-SARS-CoV-2 kusetshenziswa amasosha, eKhenya, futhi beluholwa i-KEMRI Wellcome Trust Research Programme.